- Home
- STTK vs KORE Comparison
STTK vs KORE Comparison
Compare STTK & KORE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- KORE
- Stock Information
- Founded
- STTK 2016
- KORE 2003
- Country
- STTK United States
- KORE United States
- Employees
- STTK N/A
- KORE N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- KORE Telecommunications Equipment
- Sector
- STTK Health Care
- KORE Consumer Discretionary
- Exchange
- STTK Nasdaq
- KORE Nasdaq
- Market Cap
- STTK 38.4M
- KORE 39.3M
- IPO Year
- STTK 2020
- KORE N/A
- Fundamental
- Price
- STTK $0.77
- KORE $2.31
- Analyst Decision
- STTK Hold
- KORE Hold
- Analyst Count
- STTK 4
- KORE 2
- Target Price
- STTK $3.00
- KORE $2.75
- AVG Volume (30 Days)
- STTK 229.3K
- KORE 19.6K
- Earning Date
- STTK 08-04-2025
- KORE 08-14-2025
- Dividend Yield
- STTK N/A
- KORE N/A
- EPS Growth
- STTK N/A
- KORE N/A
- EPS
- STTK N/A
- KORE N/A
- Revenue
- STTK $4,606,000.00
- KORE $282,254,000.00
- Revenue This Year
- STTK N/A
- KORE $4.66
- Revenue Next Year
- STTK N/A
- KORE $6.71
- P/E Ratio
- STTK N/A
- KORE N/A
- Revenue Growth
- STTK 69.65
- KORE N/A
- 52 Week Low
- STTK $0.69
- KORE $1.10
- 52 Week High
- STTK $4.51
- KORE $4.88
- Technical
- Relative Strength Index (RSI)
- STTK 41.85
- KORE 39.29
- Support Level
- STTK $0.73
- KORE $2.60
- Resistance Level
- STTK $0.92
- KORE $2.81
- Average True Range (ATR)
- STTK 0.07
- KORE 0.17
- MACD
- STTK 0.01
- KORE -0.04
- Stochastic Oscillator
- STTK 20.80
- KORE 20.39
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About KORE KORE Group Holdings Inc.
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.